Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables - Accured: 2021-2023

Historic Revenue - Other for Autolus Therapeutics (AUTL) over the last 1 years, with Sep 2022 value amounting to -$236.0 million.

  • Autolus Therapeutics' Revenue - Other fell 200.00% to -$236.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $435,000, marking a year-over-year decrease of 99.82%. This contributed to the annual value of $1.5 million for FY2021, which is 518.22% up from last year.
  • Per Autolus Therapeutics' latest filing, its Receivables - Accured stood at $24.9 million for Q3 2023, which was up 25.76% from $19.8 million recorded in Q2 2023.
  • Autolus Therapeutics' 5-year Receivables - Accured high stood at $24.9 million for Q3 2023, and its period low was $9,436 during Q4 2021.
  • Moreover, its 3-year median value for Receivables - Accured was $6.5 million (2022), whereas its average is $10.5 million.
  • Data for Autolus Therapeutics' Revenue - Other shows a maximum YoY crashed of 200.00% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Revenue - Other stood at $307,000 in 2018, then fell by 3.26% to $297,000 in 2019, then reached $338,000 in 2020, then decreased by 20.41% to $236.0 million in 2021, then tumbled by 200.00% to -$236.0 million in 2022.
  • Its last three reported values are -$236.0 million in Q3 2022, $166,000 for Q1 2022, and $236.0 million during Q3 2021.